OS Therapies Incorporated (OSTX)

In October 2025, the company announced positive final 2-year overall survival data from its Phase 2b trial of OST-HER2. In November 2025, Lake Street maintained a "Buy" recommendation for OSTX. In December 2025, OS Therapies announced a successful Type C meeting with the U.S. FDA and a successful pre-Marketing Authorisation Application (MAA) meeting with the UK MHRA. In January 2026, OS Therapies raised $7.53 million through warrant exercise inducement agreements and provided a corporate outlook for the first half of 2026. The stock price has experienced a significant decline over the past year, falling by approximately 68.71% from January 13, 2025, to January 12, 2026, with a share price of $1.46 as of January 12, 2026.

Traditional demand seasonality is not directly applicable to OS Therapies, Inc. as a clinical-stage biopharmaceutical company. However, historical data suggests that buying OSTX stock in April has the highest probability of a positive return, while February has the lowest probability, indicating a potential seasonality in investor sentiment or market dynamics.

OS Therapies, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma (OS) and other solid tumors. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy, and OST-tADC, a tunable Antibody-Drug Conjugate (ADC) platform. OST-HER2 is designed to help the immune system fight cancer and is being developed for the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. OST-tADC is a platform that allows for the delivery of various payloads directly into and around solid tumors. The company's mission is to address the critical need for new treatments in bone cancers affecting children and young adults.

OS Therapies, Inc. primarily focuses on the United States for the development and commercialization of its treatments, with headquarters in Grasonville and Rockville, Maryland. The company is also pursuing regulatory approvals and market authorization in the United Kingdom (UK) and the European Union (EU) for its lead product candidate, OST-HER2.

OS Therapies, Inc. has generally maintained a positive brand reputation, particularly among analysts, with a consensus rating of "Moderate Buy" or "Strong Buy" from Wall Street analysts. The average price target is $17.33, representing a significant upside from its current price. However, there was a "SHAREHOLDER ALERT" announced by Purcell & Lefkowitz LLP regarding a shareholder investigation of OS Therapies, Inc.

OS Therapies, Inc. has a mix of institutional and individual owners. As of January 12, 2026, there are 30 institutional owners and shareholders holding a total of 1,606,502 shares. Major institutional owners include CM Management, LLC, Marshall Wace, LLP, and Vanguard Group Inc. Key individual owners (insiders) include Shalom Auerbach, Paul A. Romness, and John Ciccio. Insiders collectively hold 10.30% of the stock.